Friday, July 10, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Clinical program

IB 2021-01

Phase 2 · small molecule · Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

IB 2021-01 for Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas. is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

← All The George Institute projects Phase 2 small molecule active

Internal code IB 2021-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The George Institute
Phase
Phase 2
Modality
small_molecule
Indication
Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.
Status
active
Trials
1